<DOC>
	<DOCNO>NCT02239146</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial evaluate safety escalate single dos rFXIII ( recombinant factor XIII , catridecacog ) administer follow first time myocardial revascularization require cardiopulmonary bypass ( CPB ) .</brief_summary>
	<brief_title>Safety rFXIII Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Subject undergo his/her first myocardial revascularization Previous participation ( randomisation dose ) trial Subject history cerebrovascular event ( include thrombotic haemorrhagic stroke transient ischaemic attack ( TIA ) ) and/or extramyocardial thromboembolic event , e.g. , deep vein thrombosis ( DVT ) pulmonary embolus ( PE ) Subject require preoperative ( within 30 day ) transfusion blood and/or blood product Subject current atrial fibrillation history atrial fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>